This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Alzheimer’s disease patients with cognitive impairment or dementia who were referred for amyloid PETscans had fewer hospitalizations compared with a matched control group, according to a study published October 9 in JAMA Neurology. Each participant was matched to a control Medicare beneficiary who had not undergone amyloid PET.
“To date, F-18 FDG PET findings are currently not taken into account when making a diagnosis for possible, probable, or definite neurosarcoidosis,” noted lead author Jessy Chen, MD, of Charité - Berlin University Medicine, and colleagues. The article was published January 25 in Neurological Research and Practice.
National Institutes of Health (NIH) has highlighted a study that shows cardiac PETscans can help identify people at risk for Parkinson’s disease and Lewy body dementia. Heart and brain PETscans from a study participant who developed Parkinson’s disease support a “body first” progression.
F-18 PI-2620 was first developed by researchers in Germany, and it has since been tested in studies that suggest it may be more accurate than other tau radiotracers used to diagnose Alzheimer’s disease patients based on its ability to bind more strongly to the target. in 15 patients with negative amyloid PETscans; 1.18 in
This standard has revolutionized the radiology industry, encompassing many imaging modalities such as X-rays, computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, nuclear medicine, PETscans, etc. Practicing Radiologists: access DICOM image files for studying, interpreting, and diagnosing them.
We organize all of the trending information in your field so you don't have to. Join 5,000 users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content